These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 10654009)
41. High-dose chemotherapy combined with escalating doses of cyclosporin A and an autologous bone marrow transplant for the treatment of drug-resistant solid tumors: a phase I clinical trial. Stiff PJ; Bayer R; Tan S; Camarda M; Sosman J; Peace D; Kinch L; Rad N; Loutfi S Clin Cancer Res; 1995 Dec; 1(12):1495-502. PubMed ID: 9815949 [TBL] [Abstract][Full Text] [Related]
42. A phase I-II study of high-dose melphalan, mitoxantrone and carboplatin with peripheral blood stem cell support in patients with advanced ovarian or breast carcinoma. Weaver CH; Greco FA; Hainsworth JD; Zhen B; Baldwin P; Wittlin F; Lewis M; West WH; Schwartzberg L; Buckner CD Bone Marrow Transplant; 1997 Nov; 20(10):847-53. PubMed ID: 9404925 [TBL] [Abstract][Full Text] [Related]
43. Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period. Lister J; Rybka WB; Donnenberg AD; deMagalhaes-Silverman M; Pincus SM; Bloom EJ; Elder EM; Ball ED; Whiteside TL Clin Cancer Res; 1995 Jun; 1(6):607-14. PubMed ID: 9816022 [TBL] [Abstract][Full Text] [Related]
44. Results of a pilot study of 40 patients using high-dose therapy with hematopoietic rescue after standard-dose adjuvant therapy for high-risk breast cancer. Tomás JF; Pérez-Carrión R; Escudero A; López-Lorenzo JL; López-Pascual J; Fernández-Rañada JM Bone Marrow Transplant; 1997 Feb; 19(4):331-6. PubMed ID: 9051242 [TBL] [Abstract][Full Text] [Related]
45. Cyclophosphamide/mitoxantrone/melphalan (CMA) regimen prior to autologous bone marrow transplantation (ABMT) in metastatic breast cancer. Gisselbrecht C; Extra JM; Lotz JP; Devaux Y; Janvier M; Peny AM; Guillevin L; Bremond D; Delain M; Herbrecht R; Lepage E; Maraninchi D Bone Marrow Transplant; 1996 Nov; 18(5):857-63. PubMed ID: 8932837 [TBL] [Abstract][Full Text] [Related]
46. Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patients. Stemmer SM; Hardan I; Raz H; Adamou AK; Inbar M; Gottfried M; Merrick Y; Cohen Y; Sulkes A; Ben-Baruch N; Pfeffer RP; Brenner HJ; Rizel S Bone Marrow Transplant; 2003 Apr; 31(8):655-61. PubMed ID: 12692605 [TBL] [Abstract][Full Text] [Related]
47. The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy. Cheng YC; Rondón G; Yang Y; Smith TL; Gajewski JL; Donato ML; Shpall EJ; Jones R; Hortobagyi GN; Champlin RE; Ueno NT Biol Blood Marrow Transplant; 2004 Nov; 10(11):794-804. PubMed ID: 15505610 [TBL] [Abstract][Full Text] [Related]
48. [CBDCA, etoposide and epirubicin high-dose combination chemotherapy supported by peripheral blood stem cell transplantation (PBSCT) in metastatic breast cancer]. Suwata J; Takada S; Murata N; Ishizuka N; Idezuki Y; Kobayashi M Gan To Kagaku Ryoho; 1999 Jan; 26(1):83-8. PubMed ID: 9987502 [TBL] [Abstract][Full Text] [Related]
49. Phase II study of autologous transplantation with interleukin-2-incubated peripheral blood stem cells and posttransplantation interleukin-2 in relapsed or refractory non-Hodgkin lymphoma. Van Besien K; Mehra R; Wadehra N; Stock W; Khouri I; Giralt S; Devine S; Wickrema A; Peace D; Sosman J; Gajewski J; Champlin R Biol Blood Marrow Transplant; 2004 Jun; 10(6):386-94. PubMed ID: 15148492 [TBL] [Abstract][Full Text] [Related]
50. Feasibility and low toxicity of early radiotherapy after high-dose chemotherapy and autologous stem cell transplantation for patients with high-risk stage II-III and locally advanced breast carcinoma. Stemmer SM; Pfeffer MR; Rizel S; Hardan I; Goffman J; Gezin A; Neumann A; Kitsios P; Alezra D; Brenner HJ Cancer; 2001 Jun; 91(11):1983-91. PubMed ID: 11391576 [TBL] [Abstract][Full Text] [Related]
51. Acute and late toxicity following adjuvant high-dose chemotherapy for high-risk primary operable breast cancer--a quality assessment study. Svane IM; Homburg KM; Kamby C; Nielsen DL; Roer O; Sliffsgaard D; Johnsen HE; Hansen SW Acta Oncol; 2002; 41(7-8):675-83. PubMed ID: 14651213 [TBL] [Abstract][Full Text] [Related]
52. Stem cell dose and tumorbiologic parameters as prognostic markers for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous blood stem cell support. Hensel M; Schneeweiss A; Sinn HP; Egerer G; Kornacker M; Solomayer E; Haas R; Bastert G; Ho AD Stem Cells; 2002; 20(1):32-40. PubMed ID: 11796920 [TBL] [Abstract][Full Text] [Related]
53. Autologous stem cell transplantation for high-risk Hodgkin's disease: improvement over time and impact of conditioning regimen. Subirà M; Sureda A; Martino R; García J; Altés A; Canals C; Domingo-Albós A; Brunet S; Sierra J Haematologica; 2000 Feb; 85(2):167-72. PubMed ID: 10681724 [TBL] [Abstract][Full Text] [Related]
54. Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas. Schlemmer M; Wendtner CM; Falk M; Abdel-Rahman S; Licht T; Baumert J; Straka C; Hentrich M; Salat C; Hiddemann W; Issels RD Oncology; 2006; 71(1-2):32-9. PubMed ID: 17344669 [TBL] [Abstract][Full Text] [Related]
55. Phase II pilot study of high-dose busulfan and CY followed by autologous BM or peripheral blood stem cell transplantation in patients with advanced chemosensitive breast cancer. Klumpp TR; Mangan KF; Glenn LD; Macdonald JS Bone Marrow Transplant; 1993 Apr; 11(4):337-9. PubMed ID: 8097937 [TBL] [Abstract][Full Text] [Related]
56. High-dose chemotherapy and autologous stem cell support followed by post-transplant doxorubicin and taxol as initial therapy for metastatic breast cancer: hematopoietic tolerance and efficacy. deMagalhaes-Silverman M; Hammert L; Lembersky B; Lister J; Rybka W; Ball E Bone Marrow Transplant; 1998 Jun; 21(12):1207-11. PubMed ID: 9674853 [TBL] [Abstract][Full Text] [Related]
57. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer. Lorigan P; Woll PJ; O'Brien ME; Ashcroft LF; Sampson MR; Thatcher N J Natl Cancer Inst; 2005 May; 97(9):666-74. PubMed ID: 15870437 [TBL] [Abstract][Full Text] [Related]
58. Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066. Peppercorn J; Herndon J; Kornblith AB; Peters W; Ahles T; Vredenburgh J; Schwartz G; Shpall E; Hurd DD; Holland J; Winer E Cancer; 2005 Oct; 104(8):1580-9. PubMed ID: 16118805 [TBL] [Abstract][Full Text] [Related]
59. Randomized Phase II trial of two high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group study. Stiff PJ; Shpall EJ; Liu PY; Wilczynski SP; Callander NS; Scudder SA; Jazieh AR; Samlowski W; McCoy J; Alberts DS; Gynecol Oncol; 2004 Jul; 94(1):98-106. PubMed ID: 15262126 [TBL] [Abstract][Full Text] [Related]
60. High-dose chemotherapy followed by stem cell rescue for high-risk germ cell tumors: the Stanford experience. Agarwal R; Dvorak CC; Stockerl-Goldstein KE; Johnston L; Srinivas S Bone Marrow Transplant; 2009 Apr; 43(7):547-52. PubMed ID: 18997833 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]